PAR

Par Drugs & Chemicals Share Price

 

 

Start SIP in PAR

Start SIP

Performance

  • Low
  • ₹97
  • High
  • ₹99
  • 52 Week Low
  • ₹81
  • 52 Week High
  • ₹174
  • Open Price₹98
  • Previous Close₹100
  • Volume6,776
  • 50 DMA₹95.32
  • 100 DMA₹97.92
  • 200 DMA₹109.51

Investment Returns

  • Over 1 Month + 4.31%
  • Over 3 Month -0.35%
  • Over 6 Month -5.63%
  • Over 1 Year -41.85%

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 8.6
  • PEG Ratio
  • -0.9
  • Market Cap Cr
  • 120
  • P/B Ratio
  • 1.1
  • Average True Range
  • 5
  • EPS
  • 11.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.83
  • RSI
  • 62.28
  • MFI
  • 76.08

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹97.30
-2.55 (-2.55%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹94.33
  • 50 Day
  • ₹95.32
  • 100 Day
  • ₹97.92
  • 200 Day
  • ₹109.51

Resistance and Support

100.79 Pivot Speed
  • R3 108.55
  • R2 106.28
  • R1 103.06
  • S1 97.57
  • S2 95.30
  • S3 92.08

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 106.37 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 18% is great, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 5% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 78 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-11-13 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-29 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-07 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-05-08 Audited Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.41%
0%
20.03%
6.56%

About Par Drugs & Chemicals

  • NSE Symbol
  • PAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Falgun Vallabhbhai Savani
  • ISIN
  • INE04LG01015

Similar Stocks to Par Drugs & Chemicals

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹97 As on 13 February, 2026 | 15:00

The Market Cap of Par Drugs & Chemicals is ₹119.7 Cr As on 13 February, 2026 | 15:00

The P/E ratio of Par Drugs & Chemicals is 8.6 As on 13 February, 2026 | 15:00

The PB ratio of Par Drugs & Chemicals is 1.1 As on 13 February, 2026 | 15:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23